Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
MWN-AI** Summary
Immunic, Inc., a late-stage biotechnology firm focused on innovative oral therapies for neurological and gastrointestinal disorders, has announced its participation in the 8th Annual Evercore ISI Healthcare Conference, held from December 2-4, 2025, in Coral Gables, FL. On December 4, at 9:35 am ET, CEO Daniel Vitt, Ph.D., will engage in a fireside chat discussing Immunic's strategic developments and research progress. Additionally, Jason Tardio, the President and COO, will join Dr. Vitt for one-on-one investor meetings throughout the conference.
Immunic is notable for its lead candidate, vidofludimus calcium (IMU-838), currently advancing through Phase 3 trials targeting relapsing multiple sclerosis, with anticipated data results by the end of 2026. This compound has previously shown effectiveness in Phase 2 trials for patients suffering from relapsing-remitting and progressive forms of MS. Vidofludimus calcium operates as a first-in-class activator, combining neuroprotection with anti-inflammatory and antiviral properties by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
In addition to IMU-838, Immunic is developing IMU-856, which focuses on restoring intestinal barrier functions to combat various gastrointestinal ailments, including celiac disease and inflammatory bowel disease. Furthermore, the company is in the preclinical stage of IMU-381, a next-generation therapy designed for gastrointestinal disorders.
Investors interested in Immunic's progress can access a live webcast of the conference via their website and can schedule meetings through their Evercore ISI contacts. This event presents an opportunity for stakeholders to gain insights into Immunic's current projects and future directions in the biotech space.
MWN-AI** Analysis
Immunic, Inc. (Nasdaq: IMUX) is set to showcase its advancements in biotechnology at the upcoming 8th Annual Evercore ISI Healthcare Conference, scheduled for December 2-4, 2025. This presents a strategic opportunity for investors to assess the company’s progress in developing novel oral therapies for neurologic and gastrointestinal diseases, particularly through its lead candidate, vidofludimus calcium (IMU-838).
As Immunic prepares to present at this high-profile event, it’s important to evaluate the potential implications for its stock performance. Immunic has entered late-stage clinical trials for IMU-838, and reassuringly, the drug has already demonstrated therapeutic activity in earlier phases, providing a solid foundation for investor confidence. With topline data expected by the end of 2026, any positive discussions during the conference could lead to increased investor interest and a potential uptick in share price.
Additionally, the diverse portfolio of Immunic, including its exploratory candidates like IMU-856 and IMU-381, highlights the company’s commitment to addressing prevalent health issues, which could be appealing in a post-pandemic era. Given the increasing prevalence of autoimmune and gastrointestinal diseases, Immunic's therapeutic solutions are well-positioned for market need.
However, investors should remain cautious. The biotechnology sector is inherently volatile, characterized by risks associated with clinical trial outcomes and regulatory approvals. Immunic has highlighted these uncertainties in its forward-looking statements, indicating that market conditions, including macroeconomic trends and potential impacts from global conflicts, could affect its operational capabilities.
In conclusion, while Immunic’s coming participation in the conference can stimulate interest and potentially lead to investment opportunities, investors are advised to closely monitor upcoming developments, clinical data releases, and broader market dynamics before making decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL.
A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu at: jessica.breu@imux.com.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
SOURCE Immunic, Inc.
FAQ**
Can you provide updates on the Phase 3 clinical trial timeline for vidofludimus calcium (IMU-838) in relapsing multiple sclerosis, Immunic Inc. IMUX, and any anticipated challenges that could affect the readout?
What are Immunic Inc. IMUX's strategies for addressing the competitive landscape in the neurology and gastrointestinal disease markets as you advance your product candidates?
Could you elaborate on the potential applications of IMU-856 for gastrointestinal diseases and how Immunic Inc. IMUX plans to evaluate its effectiveness in various patient populations?
What financial strategies does Immunic Inc. IMUX have in place to sustain operations and fund ongoing trials, especially considering the potential risks outlined in your forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about Immunic Inc. (NASDAQ: IMUX).
NASDAQ: IMUX
IMUX Trading
-15.16% G/L:
$1.175 Last:
4,026,747 Volume:
$1.39 Open:
